Loading
Platinum plus etoposide has been the chemotherapy backbone of small-cell lung cancer for over 40 years, and is now given with immunotherapy.
Cisplatin or carboplatin with etoposide for 4 (extensive-stage) to 4-6 (limited-stage, with concurrent radiotherapy) cycles. Response rates 60-80% but relapse is near-universal in extensive-stage disease. Carboplatin is preferred with immunotherapy and in frailer patients; cisplatin with concurrent thoracic radiotherapy in fit limited-stage patients.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Platinum DNA crosslinks plus topoisomerase-II inhibition by etoposide.
1.Platinum forms intrastrand DNA crosslinks
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1983 | Etoposide approved for SCLC; platinum-etoposide became standard in the 1980s |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3+) | - | 40% |
| Anaemia | 40% | - |
| Nausea | 50% | - |
| Alopecia | 60% | - |
Range across trials 23-45%. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Platinum + etoposide" OR ABSTRACT:"Platinum + etoposide" OR TITLE:"EP / CE" OR ABSTRACT:"EP / CE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Platinum + etoposide (EP / CE), not a curated reading list.
Shares Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy, Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares ASTRUM-005, IMpower133, CASPIAN, Small-cell lung cancer.
Shares IMpower133, CASPIAN, Extensive-stage small-cell lung cancer, Lung cancer (all types).
Shares Chemo-immunotherapy induction → maintenance intensification (SCLC), Extensive-stage small-cell lung cancer, Small-cell lung cancer, Lung cancer (all types).
Shares ASTRUM-005, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Chemo-immunotherapy induction → maintenance intensification (SCLC), Extensive-stage small-cell lung cancer, Small-cell lung cancer, Lung cancer (all types).
Shares Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy, Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer, Small-cell lung cancer.